Scopus Biopharma Inc
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3s… Read more
Scopus Biopharma Inc (SCPS) - Total Assets
Latest total assets as of June 2023: $497.55K USD
Based on the latest financial reports, Scopus Biopharma Inc (SCPS) holds total assets worth $497.55K USD as of June 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Scopus Biopharma Inc - Total Assets Trend (2017–2022)
This chart illustrates how Scopus Biopharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Scopus Biopharma Inc - Asset Composition Analysis
Current Asset Composition (December 2022)
Scopus Biopharma Inc's total assets of $497.55K consist of 99.4% current assets and 0.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 31.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $2.27K | 0.6% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2022)
This chart illustrates how Scopus Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scopus Biopharma Inc's current assets represent 99.4% of total assets in 2022, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 31.8% of total assets in 2022, down from 74.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is property, plant & equipment at 0.6% of total assets.
Scopus Biopharma Inc Competitors by Total Assets
Key competitors of Scopus Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Scopus Biopharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Scopus Biopharma Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Scopus Biopharma Inc is currently not profitable relative to its asset base.
Scopus Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 0.31 | 2.76 |
| Quick Ratio | 0.05 | 0.31 | 2.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-10.51 Million | $ -3.70 Million | $ 640.88K |
Scopus Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between Scopus Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.42 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -95.2% |
| Total Assets | $392.26K |
| Market Capitalization | $10.27K USD |
Valuation Analysis
Below Book Valuation: The market values Scopus Biopharma Inc's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Scopus Biopharma Inc's assets decreased by 95.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Scopus Biopharma Inc (2017–2022)
The table below shows the annual total assets of Scopus Biopharma Inc from 2017 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $392.26K | -95.21% |
| 2021-12-31 | $8.19 Million | +314.76% |
| 2020-12-31 | $1.97 Million | +155.81% |
| 2019-12-31 | $771.68K | +481.80% |
| 2018-12-31 | $132.64K | -37.69% |
| 2017-12-31 | $212.87K | -- |